EANS-Adhoc: Oxygen Biotherapeutics to Voluntarily Withdraw Secondary Listing from SIX Swiss Stock Exchange
28.10.2011 – 06:33
-------------------------------------------------------------------------------- ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- 28.10.2011 MORRISVILLE, NC, October 27, 2011 - Oxygen Biotherapeutics, Inc. (NASDAQ & SIX: OXBT) today announced that the SIX Swiss Stock Exchange has approved the application filed by the company on September 30, 2011, to remove the company's shares from trading on the SIX exchange. This application was filed after the Company's Board of Directors determined that the cost of maintaining the SIX listing was not justified in light of the low trading volume of the Company's shares over the past 12 months. The last day of trading for the company's common stock on the SIX will be January 30, 2012. Shares will continue to trade on the NASDAQ OMX under the symbol OXBT. end of ad-hoc-announcement ================================================================================ About Oxygen Biotherapeutics, Inc. Headquartered in Morrisville, NC, Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier product called Oxycyte® that is being formulated for both intravenous and topical delivery. The company has commercialized its DERMACYTE® line of oxygen-rich skin care products. In addition, the company is focused on PFC-based oxygen carriers for use in traumatic brain injury, decompression sickness, and topical wound healing. See www.oxybiomed.com for more information. Caution Regarding Forward-Looking Statements This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the companys judgment as of the date of this release. These statements include the management transition, and expansion of research and development of the Oxycyte product line, including the timing of the introduction of these new products. The forward-looking statements are subject to a number of risks and uncertainties including matters beyond the companys control that could lead to delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current annual report on Form 10-K filed on July 15, 2011 and current quarterly report on Form 10-Q filed on September 19, 2011. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Further inquiry note: Ellen Corliss Vice President, Corporate Communications & Investor Relations Oxygen Biotherapeutics, Inc One Copley Pkwy, Suite 490 Morrisville, NC 27560 Direct Telephone: +1 919 855 2112 Direct Fax: +1 919 806 4417 Email: e.corliss@oxybiomed.com end of announcement euro adhoc -------------------------------------------------------------------------------- issuer: Oxygen Biotherapeutics Inc. One Copley Parkway, Suite 490 US-27560 Morrisville, NC phone: +1 (919) 855 21 12 FAX: +1 (919) 806 44 17 mail: e.corliss@oxybiomed.com WWW: www.oxybiomed.com sector: Biotechnology ISIN: US69207P2092 indexes: SSIRT stockmarkets: Nasdaq: New York, Main Standard: SIX Swiss Exchange language: English